Top

Published in:

01-07-2010

Bladder Cancer: Can We Move Beyond Chemotherapy?

Author: Arlene Siefker-Radtke

Published in: Current Oncology Reports | Issue 4/2010

Abstract

Since the advent of cisplatin-based chemotherapy, cytotoxic combination chemotherapy remains the mainstay of treatment for locally advanced and metastatic urothelial malignancies. The current paradigm of combining novel agents with cytotoxic chemotherapy without any understanding of the underlying biology of urothelial cancer has limited the impact of developing novel agents for this disease. Current research investigating the biology of bladder cancer, including the role of p53, EMT, EGFR-related pathways, and anti-angiogenic pathways, may potentially impact the future development of novel agents targeting urothelial malignancies. Additionally, the use of novel gene therapy to mediate enhanced interferon expression in the bladder using adenoviral vectors, and enhancing tumor recognition strategies using the immune system with vaccines and anti-CTLA4 antibodies, are of interest. It is hoped that through these efforts we may soon move beyond the traditional cytotoxic chemotherapy paradigm, developing combinations that are more active and less toxic for all patients with urothelial cancer.

Sternberg CN, Yagoda A, Scher HI, et al.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133:403–407.PubMed

von der Maase H, Hansen SW, Roberts JT, et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068–3077.PubMed

Grossman HB, Natale RB, Tangen CM, et al.: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [erratum appears in N Engl J Med 2003, 349:1880]. N Engl J Med 2003, 349:859–866.CrossRefPubMed

Logothetis CJ, Dexeus FH, Finn L, et al.: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990, 8:1050–1055.PubMed

Logothetis CJ, Finn LD, Smith T, et al.: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 1995, 13:2272–2277.PubMed

Seidman AD, Scher HI, Gabrilove JL, et al.: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993, 11:408–414.PubMed

Loehrer PJ Sr, Elson P, Dreicer R, et al.: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1994, 12:483–488.PubMed

Bamias A, Aravantinos G, Deliveliotis C, et al.: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004, 22:220–228.CrossRefPubMed

Siefker-Radtke AO, Millikan RE, Tu SM, et al.: Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002, 20:1361–1367.CrossRefPubMed

10.

Sternberg CN, de Mulder PH, Schornagel JH, et al.: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001, 19:2638–2646.PubMed

11.

Siefker-Radtke A, Millikan, RE, Kamat, AM, et al.: A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine, and ifosfamide (CGI) in locally advanced urothelial cancer: Final results from the M. D. Anderson Cancer Center. J Clin Oncol 2008, 26:269s.

12.

Bajorin DF, McCaffrey JA, Dodd PM, et al.: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000, 88:1671–1678.CrossRefPubMed

13.

•• Siefker-Radtke A, Kamat A, Williams D, et al.: A phase II randomized four-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center. J Clin Oncol 2009, 27:251s. This clinical trial used a novel statistical design in sequential therapy that incorporates response to continue treatment that is working, with early re-randomization in the setting of suboptimal response.

14.

• Milowsky MI, Nanus DM, Maluf FC, et al.: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2009, 27:4062–4067. This is a sequential clinical trial design using a fixed schedule of chemotherapy.

15.

Thall PF, Millikan RE, Sung HG: Evaluating multiple treatment courses in clinical trials. Stat Med 2000, 19:1011–1028.CrossRefPubMed

16.

• Siefker-Radtke AO, Kamat AM, Grossman HB, et al.: Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009, 27:2592–2597. This is the first clinical trial in small cell urothelial cancer. Though it is a small clinical trial, it suggests a potential impact for neoadjuvant chemotherapy in small cell of the bladder.

17.

Siefker-Radtke AO, Gee J, Shen Y, et al.: Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol 2003, 169:1295–1298.CrossRefPubMed

18.

Shariat SF, Lotan Y, Karakiewicz PI, et al.: p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009, 182:907–913.CrossRefPubMed

19.

Millikan R, Dinney C, Swanson D, et al.: Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001, 19:4005–4013.PubMed

20.

Mhawech-Fauceglia P, Fischer G, Beck A, et al.: Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 2006, 32:439–444.CrossRefPubMed

21.

Slaton JW, Millikan R, Inoue K, et al.: Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004, 171:570–574.CrossRefPubMed

22.

Sen S, Zhou H, Zhang RD, et al.: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002, 94:1320–1329.PubMed

23.

Park HS, Park WS, Bondaruk J, et al.: Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008, 100:1401–1411.CrossRefPubMed

24.

Nguyen PL, Swanson PE, Jaszcz W, et al.: Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994, 101:166–176.PubMed

25.

Blehm KN, Spiess PE, Bondaruk JE, et al.: Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 2006, 12:4671–4677.CrossRefPubMed

26.

Black PC, Brown GA, Inamoto T, et al.: Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008, 14:1478–1486.CrossRefPubMed

27.

•• Adam L, Zhong M, Choi W, et al.: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009, 15:5060–5072. This recent publication suggests a role for miR-200 as a regulatory mechanism for EMT in urothelial cancer.

28.

Jimenez RE, Hussain M, Bianco FJ Jr, et al.: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001, 7:2440–2447.PubMed

29.

Lonn U, Lonn S, Friberg S, et al.: Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995, 1:1189–1194.PubMed

30.

Lee SE, Chow NH, Chi YC, et al.: Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 1994, 14:1317–1324.PubMed

31.

Hussain M, Petrylak D, Dunn R, et al.: Trastuzumab (T), Paclitaxel (P), Carboplatin (C), and Gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Oncol 2005, 23:379s.CrossRef

32.

Goddard JC, Sutton CD, Furness PN, et al.: Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003, 9:2583–2586.PubMed

33.

Bochner BH, Cote RJ, Weidner N, et al.: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995, 87:1603–1612.CrossRefPubMed

34.

Crew JP, O'Brien T, Bradburn M, et al.: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997, 57:5281–5285.PubMed

35.

Yang CC, Chu KC, Yeh WM: The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004, 22:1–6.PubMed

36.

Bernardini S, Fauconnet S, Chabannes E, et al.: Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001, 166:1275–1279.CrossRefPubMed

37.

Benedict WF, Tao Z, Kim CS, et al.: Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004, 10:525–532.CrossRefPubMed

38.

Nagabhushan TL, Maneval DC, Benedict WF, et al.: Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Rev 2007, 18:389–394.CrossRefPubMed

39.

•• Sharma P, Shen Y, Wen S, et al.: CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sc U S A 2007, 104:3967–3972. This recent tissue-based study suggests the potential impact of tumor recognition by the immune system.

40.

Sharma P, Gnjatic S, Jungbluth AA, et al.: Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 2003, 3:19.PubMed

41.

•• Sharma P, Bajorin DF, Jungbluth AA, et al.: Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008, 31:849–857. This clinical trial uses vaccine to induce immune responses in urothelial cancer patients.

Title: Bladder Cancer: Can We Move Beyond Chemotherapy?
Author: Arlene Siefker-Radtke
Publication date: 01-07-2010
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 4/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-010-0104-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

STEPP for the EGFR Inhibitor–Induced Rash—Definitely a Step in the Right Direction

Testicular Cancer: When Less is More

How to Discuss Errors and Adverse Events with Cancer Patients

Lung Cancer Screening: An Update, Discussion, and Look Ahead

Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety

The Role of Stereotactic Body Radiotherapy in the Management of Non-Small Cell Lung Cancer: An Emerging Standard for the Medically Inoperable Patient?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer